Trial Profile
First-line single-agent Panitumumab in the Japanese frail patients with wild-type RAS unresectable colorectal cancer: A phase II study(OGSG 1602)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Jul 2023
Price :
$35
*
At a glance
- Drugs Panitumumab (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- Acronyms OGSG 1602
- 05 Jul 2023 Final results reporting survival analysis data from this trial published in the Oncologist
- 08 Jun 2021 Results (n=34) of survival efficacy analysis presented at the 57th Annual Meeting of the American Society of Clinical Oncology
- 02 Nov 2020 Status changed from active, no longer recruiting to completed.